Document:

Threshold
Pharmaceuticals, Inc.

Stock
Option Grant Notice

(2014
Equity Incentive Plan)

 

Option
Grant

Non-Employee
Director Compensation Policy

 

Threshold Pharmaceuticals, Inc. (the “Company”),
pursuant to its 2014 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option
to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms
and conditions as set forth in this notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached
hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the
Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms
in this notice and the Plan, the terms of the Plan will control.

 

	Optionholder:	

	Date of Grant:	

	Vesting Commencement Date:	

	Number of Shares Subject to Option:	

	Exercise Price (Per Share):	

	Total Exercise Price:	

	Expiration Date:	

 

	Type of Grant:	x  Nonstatutory Stock Option
	 	 
	Exercise Schedule:	

x  Same
as Vesting Schedule

	 	 
	Vesting Schedule:	[_________________]
	 	 
	Payment:	By one or a combination of the following items (described in the Option Agreement):
	 	 	 
	 	x	By cash, check, bank draft or money order payable to the Company
	 	x	Pursuant to a Regulation T Program if the shares are publicly traded
	 	x	By delivery of already-owned shares if the shares are publicly traded
	 	x     If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company’s consent at the time of exercise, by a “net exercise” arrangement

 

    	 

    	 

    

  

Additional Terms/Acknowledgements:
Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement and the
Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended
or revised except as provided in the Plan.  Optionholder further acknowledges that as
of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between
Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations
on that subject with the exception of (i) equity awards previously granted and delivered to Optionholder, (ii) any compensation
recovery policy that is adopted by the Company or is otherwise required by applicable law and (iii) the Threshold Pharmaceuticals,
Inc. Non-Employee Director Compensation Policy or any other arrangement with the Company that would provide for vesting acceleration
of this option upon the terms and conditions set forth therein. 

 

By accepting this option, Optionholder
acknowledges having received and read this Stock Option Grant Notice, the Option Agreement and the Plan and agrees to all of the
terms and conditions set forth in these documents. Furthermore, by accepting this option, Optionholder consents to receive such
documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained
by the Company or another third party designated by the Company.

 

	Threshold Pharmaceuticals, Inc.	 	Optionholder:
	 	 	 
	By:	     	 	   
	Signature	 	Signature
	Title: 	                            	 	Date: 	                      
	Date:	          	 	 	     

 

Attachments:
Option Agreement, 2014 Equity Incentive Plan and Notice of Exercise

 

    	 

    	 

    

  

Threshold
Pharmaceuticals, Inc.

2014
Equity Incentive Plan

 

Option
Agreement

(Incentive
Stock Option or
Nonstatutory Stock Option)

 

Pursuant to your Stock
Option Grant Notice (“Grant Notice”) and this Option Agreement, Threshold Pharmaceuticals, Inc. (the
“Company”) has granted you an option under its 2014 Equity Incentive Plan (the “Plan”)
to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated
in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date
of Grant”). This Option Agreement shall be deemed to be agreed to by the Company and you upon the signing or electronically
accepting by you of the Grant Notice to which it is attached. If there is any conflict between the terms in this Option Agreement
and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant
Notice but defined in the Plan will have the same definitions as in the Plan.

 

The details of your
option, in addition to those set forth in the Grant Notice and the Plan, are as follows:

 

1.          Vesting.
Subject to the provisions contained herein, your option will vest as provided in your Grant Notice, subject to the potential acceleration
described below in this Section 1. Vesting will cease upon the termination of your Continuous Service.

 

(a)          Fundamental
Transaction. The provisions of this Section 1(a) and not Section 9(c) of the Plan will apply to your option. In the event of
a Fundamental Transaction while you remain a member of the Board who is not an employee of the Company or any parent or subsidiary
of the Company (a “Non-Employee Director”), the shares subject to your option at such time will become
automatically vested in full so that your option will, immediately prior to the effective date of the Fundamental Transaction,
become exercisable for all of the shares of Common Stock subject to your option and may be exercised for any or all of such vested
shares. Immediately following the consummation of the Fundamental Transaction, your option will terminate and cease to be outstanding,
except to the extent assumed by the successor corporation (or Affiliate thereof). If your option is assumed in connection with
the Fundamental Transaction it will be appropriately adjusted, immediately after such Fundamental Transaction, to apply to the
number and class of securities which would have been issuable to you in consummation of such Fundamental Transaction had your option
been exercised immediately prior to such Fundamental Transaction. Appropriate adjustments will also be made to the exercise price
payable per share under your option, provided that the aggregate exercise price payable for such securities will remain the same.
To the extent the actual holders of Common Stock receive cash consideration for their Common Stock in consummation of the Fundamental
Transaction, the successor corporation may, in connection with the assumption of your outstanding option, substitute one or more
shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in
such Fundamental Transaction.

 

    	1

    	 

    

   

(b)          Change
in Control. In the event of a Change in Control while you remain a Non-Employee Director, the shares of Common Stock at the
time subject to your option that is outstanding, but not otherwise vested, will automatically vest in full so that your option
will, immediately prior to the effective date of the Change in Control, become exercisable for all the shares of Common Stock subject
to your option as fully vested shares and may be exercised for any or all of those vested shares. Your option will remain exercisable
for such fully vested shares until the Expiration Date indicated in your Grant Notice or sooner termination of the option term
in connection with a Change in Control.

 

2.          Number
of Shares and Exercise Price. The number of shares of Common Stock subject to your option and your exercise price per
share in your Grant Notice will be adjusted for Capitalization Adjustments.

 

3.          Exercise
Restriction for Non-Exempt Employees. If you are an Employee eligible for overtime compensation under the Fair Labor
Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided
in the Plan, you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from
the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions of the
Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary
in the case of (i) your death or disability, (ii) a Fundamental Transaction in which your option is not assumed, continued or substituted,
(iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s
benefit plans).

 

4.          Exercise
prior to Vesting (“Early Exercise”). If permitted in your Grant Notice (i.e., the “Exercise
Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your option, you may elect at
any time that is both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all
or part of your option, including the unvested portion of your option; provided, however, that:

 

(a)          a
partial exercise of your option will be deemed to cover first vested shares of Common Stock and then the earliest vesting installment
of unvested shares of Common Stock;

 

(b)          any
shares of Common Stock so purchased from installments that have not vested as of the date of exercise will be subject to the purchase
option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement;

 

(c)          you
will enter into the Company’s form of Early Exercise Stock Purchase Agreement with a vesting schedule that will result in
the same vesting as if no early exercise had occurred; and

 

(d)          if
your option is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant)
of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable
for the first time by you during any calendar year (under all plans of the Company and its Affiliates) exceeds one hundred thousand
dollars ($100,000), your option(s) or portions thereof that exceed such limit (according to the order in which they were granted)
will be treated as Nonstatutory Stock Options.

 

    	2

    	 

    

 

5.          Method
of Payment. You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the
exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by
your Grant Notice, which may include one or more of the following:

 

(a)          Provided
that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated
by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the
Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds.
This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to
cover”.

 

(b)          Provided
that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation)
of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests,
and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion
of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such
shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common
Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s
stock.

 

(c)          If
this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net exercise”
arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option
by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay
any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted
form of payment. Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter
if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as
a result of such exercise, and (iii) are withheld to satisfy tax withholding obligations.

 

6.          Whole
Shares. You may exercise your option only for whole shares of Common Stock.

 

7.          Securities
Law Compliance. In no event may you exercise your option unless the shares of Common Stock issuable upon such exercise
are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance
of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply
with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines
that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required
for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).

 

    	3

    	 

    

 

8.          Term.
You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your
option expires, subject to the provisions of Section 5(h) of the Plan and the provisions of Section 1(a) of this Option Agreement,
upon the earliest of the following:

 

(a)          immediately
upon the termination of your Continuous Service for Cause;

 

(b)          three
(3) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death
(except as otherwise provided in Section 8(e) below); provided, however, that if during any part of such three (3) month
period your option is not exercisable solely because of the condition set forth in the section above relating to “Securities
Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for
an aggregate period of three (3) months after the termination of your Continuous Service; provided further, if during any
part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the Company’s
insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable
for an aggregate period of three (3) months (that need not be consecutive) after the termination of your Continuous Service during
which the sale of the Common Stock received upon exercise of your option would not be in violation of the Company’s insider
trading policy. Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within
six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of
Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after
the Date of Grant, and (B) the date that is three (3) months (that need not be consecutive) after the termination of your Continuous
Service, and (y) the Expiration Date;

 

(c)          three
(3) months following the beginning of your leave of absence (other than a personal or medical leave of absence approved by an authorized
representative of the Company with employment guaranteed upon return) (except as otherwise provided in Section 8(e) below);

 

(d)          twelve
(12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 8(e))
below;

 

(e)          eighteen
(18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous
Service terminates for any reason other than Cause;

 

(f)          the
Expiration Date indicated in your Grant Notice; or

 

(g)          the
day before the tenth (10th) anniversary of the Date of Grant.

 

    	4

    	 

    

 

If your option is an
Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code
requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your option’s
exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company
has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that
your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate
as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months
after the date your employment with the Company or an Affiliate terminates.

 

9.          Exercise.

 

(a)          You
may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during
its term by delivering a Notice of Exercise (in a written or electronic form designated by the Company) or taking such other action
as the Company may require together with delivering the exercise price and any applicable withholding taxes to the Company’s
Secretary or to such other person as the Company may designate (such as any broker designated by the Company to effect option exercises)
during regular business hours, together with such additional documents as the Company may then require.

 

(b)          By
exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into
an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason
of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are
subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise.

 

(c)          If
your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within
fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option
that occurs within two (2) years after the Date of Grant or within one (1) year after such shares of Common Stock are transferred
upon exercise of your option.

 

10.         Transferability.
Except as otherwise provided in this Section 10, your option is not transferable, except by will or by the laws of
descent and distribution, and is exercisable during your life only by you. 

 

(a)          Certain
Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to
a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law)
while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.

 

    	5

    	 

    

  

(b)          Domestic
Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you
and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant
to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as
permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer.
You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic
relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations
order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory
Stock Option as a result of such transfer.

  

(c)          Beneficiary
Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written
notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises,
designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or
other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your
estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration
resulting from such exercise.

 

11.         Option
not a Service Contract. Your option is not an employment or service contract, and nothing in your option will be deemed
to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the
Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate,
their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a
Director or Consultant for the Company or an Affiliate.

 

12.         Withholding
Obligations.

 

(a)          At
the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize
withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by
means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve
Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding
obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.

 

(b)          If
this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with
any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable
to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the
Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount
as may be necessary to avoid classification of your option as a liability for financial accounting purposes). If the date of determination
of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant
to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code,
covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is
otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option.
Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common
Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences
to you arising in connection with such share withholding procedure shall be your sole responsibility.

 

    	6

    	 

    

 

(c)          You
may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly,
you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation
to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein,
if applicable, unless such obligations are satisfied.

 

13.         Tax
Consequences. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation
programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers,
Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular,
you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the
Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there
is no other impermissible deferral of compensation associated with the option.

 

14.         Notices.
Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively
given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United
States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion,
decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent
to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery
and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third
party designated by the Company.

 

15.         Governing
Plan Document. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part
of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be
promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan,
the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option)
is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing
regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable
law.

 

16.         Other
Documents. You hereby acknowledge receipt of and the right to receive a document providing the information required
by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt
of the Company’s policy permitting certain individuals to sell shares only during certain “window” periods and
the Company’s insider trading policy, in effect from time to time.

 

    	7

    	 

    

 

17.         Arbitration.
All disputes, claims, or causes of action, in law or equity, arising from or relating to the enforcement, breach, performance,
or interpretation of this Agreement and the Plan will be finally resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16,
and to the fullest extent permitted by law, by final, binding and confidential arbitration in accordance with the then existing
rules of the American Arbitration Association. The arbitration will be conducted in the county in Santa Clara County, California.
Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction over it; provided that nothing
in this Agreement shall prevent either party from applying to a court of competent jurisdiction to obtain temporary relief pending
resolution of the dispute through arbitration.

 

18.         Effect
on Other Employee Benefit Plans. The value of this option will not be included as compensation, earnings, salaries,
or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate,
except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any
of the Company’s or any Affiliate’s employee benefit plans.

 

19.         Voting
Rights. You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be
issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights
as a stockholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create
or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.

 

20.         Severability.
If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid,
such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful
or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible,
be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible
while remaining lawful and valid.

 

21.         Miscellaneous.

 

(a)          The
rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants
and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.

 

(b)          You
agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company
to carry out the purposes or intent of your option.

 

(c)          You
acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel
prior to executing and accepting your option, and fully understand all provisions of your option.

  

    	8

    	 

    

 

(d)          This
Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies
or national securities exchanges as may be required.

 

(e)          All
obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the
existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially
all of the business and/or assets of the Company.

 

***

 

This Option Agreement
will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.

 

    	9PLACEMENT AGENT AGREEMENT

 

May ______, 2014

 

Dawson James Securities, Inc.

1 North Federal Highway

Boca Raton, Florida 33432

 

Ladies and Gentlemen:

 

This letter (the “Agreement”)
constitutes the placement agent agreement between FreeSeas, Inc., a Marshall Islands corporation (the “Company”)
and Dawson James Securities, Inc. (the “Placement Agent”) pursuant to which Dawson shall serve as the exclusive
placement agent (the “Services”) for the Company, on a best efforts basis, in connection with the proposed offer
and placement (the “Offering”) by the Company of its securities (the “Securities”). The Company
and Dawson shall mutually agree to the terms of the Offering and the Securities, and nothing in this Agreement may be construed
to suggest that Dawson would have the power or authority to bind the Company or an obligation for the Company to issue any Securities
or complete the Offering. The Company expressly acknowledges and agrees that Dawson’s obligations hereunder are on a reasonable
best “efforts basis” only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase
the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing
the Securities. 

 

1.          Appointment
of Placement Agent & the Description of the Offering.

 

(a)          The
Company hereby agrees to appoint the Placement Agent as its exclusive placement agent, and the Placement Agent agrees to serve
as the exclusive placement agent, in connection with an issuance and sale of the Securities to be offered and sold by the Company
pursuant to a registration statement filed under the Securities Act of 1933, as amended (the “1933 Act”) on
Form F-1 (File No. 333-195166). The timing and terms of such offering (the “Offering”) will be subject to market
conditions, the receipt of necessary regulatory clearances, and negotiations between the Company and the Placement Agent. The Placement
Agent will act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no guarantee of the successful
placement of the Securities, or any portion thereof, in the Offering. The Placement Agent shall act solely as the Company’s
agent and not as principal. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on
its behalf in connection with the Offering (as defined below). The Placement Agent shall have no authority to bind the Company
with respect to any prospective offer to purchase any Securities and the Company shall have the sole right to accept offers to
purchase Securities and may reject any such offer, in whole or in part.

 

(b)          The
term of the Placement Agent’s exclusive engagement will commence upon the execution of this Agreement and will terminate
at the earlier of the closing of the Offering or 11:59 p.m. (New York Time) on May 31, 2014 (the “Exclusive Term”).

 

(c)          Nothing
in this Agreement shall be construed to limit the ability of the Placement Agent or its Affiliates to pursue, investigate, analyze,
invest in, or engage in investment banking, financial advisory or any other business relationship with any Persons (as defined
below). As used in this Agreement: (i) “Persons” means an individual or corporation, partnership, trust, incorporated
or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision
thereof) or other entity of any kind and (ii) “Affiliate” means any Person that, directly or indirectly through
one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and
construed under Rule 405 under the 1933 Act. 

 

(d)          The
Securities to be offered directly to various investors (each, an “Investor” and, collectively, the “Investors”)
in the Offering may include but are not limited to a series of preferred stock designated as the “Series D Convertible Preferred
Stock” (the “Preferred Stock”), the shares of Common Stock (as defined below) issuable upon conversion
of the Preferred Stock (the “Conversion Shares”), warrants to purchase Common Stock (the “Warrants”)
and the shares of Common Stock issuable upon exercise or exchange of the Warrants (the “Warrant Shares”). The
Securities offered to the Investors shall be offered to all Investors on the same terms and conditions.

 

    	1

    	 

    

 

 

(e)          Subject
to the terms and conditions hereof, payment of the purchase price for the Securities to be offered in the Offering and delivery
of such Securities shall be made at one closing (the “Closing” and the date on which the Closing occurs, the
“Closing Date”).

 

(f)          Under
no circumstances will the Placement Agent or any of its Affiliates be obligated to purchase any of the Securities for its own
account.

 

(g)          On
the Closing Date, the Company shall pay to the Placement Agent the fees and expenses set forth below:

 

(i)          A
cash fee equal to 5% of the aggregate gross proceeds received by the Company from the sale of the Securities; provided that notwithstanding
the foregoing, the parties agree that solely with respect to the party or parties set forth on Annex A, the cash fee payable
shall be equal to 2% of the aggregate gross proceeds received by the Company from the sale of the Securities, subject to a maximum
of 2.6% of the Offering proceeds, or $650,000 if the maximum Offering is completed.

 

(ii)         Subject
to the limitations set forth in Financial Industry Regulatory Authority (“FINRA”) Rule 5110(f)(K), a cash fee
equal to 7% of the cash proceeds received from a cash exercise of the Warrants, subject to a maximum of 3.64% of the Offering
proceeds, or $910,000 if the maximum Offering is completed.

 

(iii)        Reimbursement
of certain expenses incurred by the Placement Agent in connection with the Offering and specified in Section 6 hereof.

 

2.          Representations
and Warranties of the Company. As of the date and time of the execution of this Agreement and
as of the Closing Date, the Company represents and warrants to the Placement Agent and to each of the Investors as follows in
this Section 2:

 

(a)          Organization
and Qualification. Each of the Company and each of its Subsidiaries (as defined below) are entities duly organized and validly
existing and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authorization
to own their properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each
of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every
jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. “Material
Adverse Effect” means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including
results thereof), condition (financial or otherwise) or prospects of the Company and its Subsidiaries, taken as a whole, (ii)
the transactions contemplated hereby or in any of the other Transaction Documents (as defined below) or (iii) the authority or
ability of the Company to perform any of its obligations under any of the Transaction Documents. Other than the Persons set forth
on Schedule 2(a), the Company has no Subsidiaries. “Subsidiaries” means any Person in which the Company,
directly or indirectly, (I) owns a majority of the outstanding capital stock or holds a majority of equity or similar interest
of such Person or (II) controls or operates all or any material part of the business, operations or administration of such Person,
and each of the foregoing, is individually referred to in this Agreement as a “Subsidiary.”

 

    	2

    	 

    

 

 

(b)          Authorization;
Enforcement; Validity. The Company has the requisite power and authority to enter into and perform its obligations under this
Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof. The
execution and delivery of this Agreement and the other Transaction Documents by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Preferred Stock and the
reservation for issuance and issuance of the Conversion Shares issuable upon conversion of the Preferred Stock and the issuance
of the Warrants and the reservation for issuance and issuance of the Warrant Shares issuable upon exercise of the Warrants) have
been duly authorized by the Company’s board of directors and (other than the filing with the SEC of one or more prospectuses
or prospectus supplements and any other filings as may be required by any state securities agencies (collectively, the “Required
Approvals”)) no further filing, consent or authorization is required by the Company, its board of directors or its stockholders
or other governing body of the Company. This Agreement has been, and the other Transaction Documents will be prior to the Closing,
duly executed and delivered by the Company, and each constitutes the legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with its respective terms, except as such enforceability may be limited by general principles
of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution
may be limited by federal or state securities law. “Transaction Documents” means, collectively, this Agreement,
the Warrants, the Certificate of Designation and each of the other agreements and instruments entered into or delivered by any
of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time.

 

(c)          Issuance
of Securities. The issuance of the Preferred Stock and the Warrants are duly authorized and, upon issuance in accordance with
the terms of the Transaction Documents, will be validly issued, fully paid and non-assessable and free from all preemptive or similar
rights, taxes, liens, charges and other encumbrances with respect to the issue thereof. As of the Closing, the Company shall have
reserved from its duly authorized capital stock not less than 133% of the sum of (i) the maximum number of Conversion Shares issuable
upon conversion of the Preferred Stock (assuming for purposes hereof that the Preferred Stock is convertible at the Conversion
Price (as defined in the Certificate of Designation) and without taking into account any limitations on the conversion of the Preferred
Stock set forth in the Certificate of Designation), and (ii) the maximum number of Warrant Shares issuable upon exercise of the
Warrants (without taking into account any limitations on the exercise of the Warrants set forth therein). The issuance of the Conversion
Shares is duly authorized, and upon conversion of the Preferred Stock in accordance with the Certificate of Designation, the Conversion
Shares, when issued, will be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, taxes,
liens, charges and other encumbrances with respect to the issue thereof, with the holders being entitled to all rights accorded
to a holder of Common Stock. The issuance of the Warrant Shares is duly authorized, and upon exercise in accordance with the Warrants,
the Warrant Shares, when issued, will be validly issued, fully paid and non-assessable and free from all preemptive or similar
rights, taxes, liens, charges and other encumbrances with respect to the issue thereof, with the holders of the Warrant Shares
being entitled to all rights accorded to a holder of Common Stock. The issuance by the Company of the Securities has been registered
under the 1933 Act, the Securities will be issued pursuant to the Registration Statement (as defined below) and all of the Securities
will be freely transferable and freely tradable by each of the Investors without restriction. Prior to the Closing Date, the Registration
Statement will be effective and available for the issuance of the Securities thereunder and the Company will not have received
any notice that the SEC has issued or intends to issue a stop-order with respect to the Registration Statement or that the SEC
otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, or intends
or has threatened in writing to do so. The “Plan of Distribution” section under the Registration Statement permits
the issuance and sale of the Securities hereunder and as contemplated by the other Transaction Documents. Upon receipt of the applicable
Securities, each Investor will have good and marketable title to the applicable Securities. “Common Stock” means
(i) the Company’s shares of common stock, $0.001 par value per share, and (ii) any capital stock into which such common
stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(d)          No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Preferred Stock,
the Warrants, the Conversion Shares and Warrant Shares and the reservation for issuance of the Conversion Shares and Warrant Shares)
will not (i) result in a violation of the Articles of Incorporation (as defined below) (including, without limitation, any certificates
of designation contained therein) or other organizational documents of the Company or any of its Subsidiaries, or Bylaws (as defined
below), (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Company or any of its Subsidiaries is a party or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including, without limitation, foreign, federal and state securities laws and regulations and the rules and
regulations of the Nasdaq Capital Market (the “Principal Market”)) applicable to the Company or any of its Subsidiaries
or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, other than, in the case of clause
(ii) above, such conflicts, defaults or rights that could not reasonably be expected to have a Material Adverse Effect.

 

    	3

    	 

    

 

 

(e)          Consents.
The Company is not required to obtain any consent from, authorization or order of, or make any filing or registration with (other
than the filing of the Required Approvals), any court, governmental agency or any regulatory or self-regulatory agency or any other
Person in order for it to execute, deliver or perform any of its obligations under, or contemplated by, the Transaction Documents,
in each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which
the Company is required to obtain at or prior to the Closing have been obtained or effected on or prior to the Closing Date, and
neither the Company nor any of its Subsidiaries are aware of any facts or circumstances which might prevent the Company from obtaining
or effecting any of the registration, application or filings contemplated by the Transaction Documents.

 

(f)          Dilutive
Effect. The Company understands and acknowledges that the number of Conversion Shares and Warrant Shares may increase in certain
circumstances. The Company further acknowledges that its obligation to issue the Conversion Shares upon conversion of the Preferred
Stock and the Warrant Shares upon exercise of the Warrants in accordance with this Agreement, the Certificate of Designation and
the Warrants is absolute and unconditional (other than the conditions set forth in this Agreement, in the Certificate of Designation
and in the Warrants), regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders
of the Company.

 

(g)          Application
of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill (including,
without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under the Articles of Incorporation,
Bylaws or other organizational documents or the laws of the jurisdiction of its incorporation or otherwise which is or could become
applicable to any Investor as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s
issuance of the Securities and any Investor’s ownership of the Securities. The Company and its board of directors have taken
all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar arrangement relating to accumulations
of beneficial ownership of shares of Common Stock or a change in control of the Company or any of its Subsidiaries.

 

(h)          SEC
Documents; Financial Statements. During the two (2) years prior to the date hereof, the Company has timely filed all reports,
schedules, forms, statements and other documents required to be filed by it with the Securities and Exchange Commission (the “SEC”
or “Commission”) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the
“1934 Act”) (all of (i) the foregoing filed prior to the date hereof and all exhibits included therein and financial
statements, notes and schedules thereto and documents incorporated by reference therein and (ii) the Registration Statement, being
hereinafter referred to as the “SEC Documents”). The Company has delivered to the Placement Agent true, correct
and complete copies of each of the SEC Documents not available on the EDGAR system. As of their respective dates, the SEC Documents
complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder
applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates,
the financial statements of the Company included in the SEC Documents complied in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. Such
financial statements have been prepared in accordance with generally accepted accounting principles, consistently applied, during
the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the
case of unaudited interim statements, to the extent they may exclude the footnotes or may be condensed or summary statements) and
fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations
and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which
will not be material, either individually or in the aggregate). No other information provided by or on behalf of the Company to
the Placement Agent or any of the Investors which is not included in the SEC Documents contains any untrue statement of a material
fact or omits to state any material fact necessary in order to make the statements therein not misleading, in the light of the
circumstance under which they are or were made.

 

    	4

    	 

    

 

 

(i)          Absence
of Certain Changes. Since the date of the Company’s most recent audited financial statements contained in a Form 20-F,
except as disclosed in the SEC Documents filed subsequent to such Form 20-F, there has been no material adverse change and no material
adverse development in the business, assets, liabilities, properties, operations (including results thereof), condition (financial
or otherwise) or prospects of the Company and its Subsidiaries, taken as a whole. Since the date of the Company’s most recent
audited financial statements contained in a Form 20-F, neither the Company nor any of its Subsidiaries has (i) declared or paid
any dividends, (ii) sold any assets outside of the ordinary course of business or (iii) made any capital expenditures outside of
the ordinary course of business. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant
to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the
Company or any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary
bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company and its
Subsidiaries, on a consolidated basis, are not, and after giving effect to the transactions contemplated hereby to occur at the
Closing will not be, Insolvent (as defined below). “Insolvent” means, with respect to the Company and its Subsidiaries,
on a consolidated basis, (i) the present fair saleable value of the Company’s and its Subsidiaries’ assets is less
than the amount required to pay the Company’s and its Subsidiaries’ total Indebtedness (as defined below), (ii) the
Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent or otherwise, as such debts
and liabilities become absolute and matured or (iii) the Company and its Subsidiaries intend to incur or believe that they will
incur debts that would be beyond their ability to pay as such debts mature. Neither the Company nor any of its Subsidiaries has
engaged in any business or in any transaction, and is not about to engage in any business or in any transaction, for which the
Company’s or such Subsidiary’s remaining assets constitute unreasonably small capital.

 

(j)          No
Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has occurred
or exists, or could reasonably be expected to occur or exist, with respect to the Company, any of its Subsidiaries or any of their
respective businesses, properties, liabilities, prospects, operations (including results thereof) or condition (financial or otherwise)
that (i) would be required to be disclosed by the Company under applicable laws on a registration statement on Form F-1 filed with
the SEC relating to an issuance and sale by the Company of its Common Stock to the holders of its Common Stock and which has not
been publicly announced, (ii) could have a material adverse effect on any Investor’s investment in the Company contemplated
by this Agreement or (iii) could have a Material Adverse Effect.

 

(k)          Conduct
of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default
under its Articles of Incorporation, any certificate of designation, preferences or rights of any other outstanding series of preferred
stock of the Company or any of its Subsidiaries or Bylaws or their organizational charter, certificate of formation or certificate
of incorporation or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree
or order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and neither the Company
nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases for possible violations
which could not, individually or in the aggregate, have a Material Adverse Effect. Without limiting the generality of the foregoing,
except as disclosed in the SEC Documents, the Company is not in violation of any of the rules, regulations or requirements of the
Principal Market and has no knowledge of any facts or circumstances that could reasonably lead to delisting or suspension of the
Common Stock by the Principal Market in the foreseeable future. Since January 1, 2013, (i) the Common Stock has been listed or
designated for quotation on the Principal Market, (ii) trading in the Common Stock has not been suspended by the SEC or the Principal
Market and (iii) except as disclosed in the SEC Documents, the Company has received no communication, written or oral, from the
SEC or the Principal Market regarding the suspension or delisting of the Common Stock from the Principal Market. The Company and
each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory authorities
necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits
would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has
received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.

 

(l)          Foreign
Corrupt Practices. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any director, officer,
agent, employee or other Person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for,
or on behalf of, the Company or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment
or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or
domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other
unlawful payment to any foreign or domestic government official or employee.

 

    	5

    	 

    

 

 

(m)          Sarbanes-Oxley
Act. The Company and each Subsidiary is in material compliance with all applicable requirements of the Sarbanes-Oxley Act of
2002 and all applicable rules and regulations promulgated by the SEC thereunder.

 

(n)          Transactions
With Affiliates. Except as disclosed in the SEC Documents, none of the officers, directors, employees or affiliates of the
Company or any of its Subsidiaries is presently a party to any transaction with the Company or any of its Subsidiaries (other than
for ordinary course services as employees, officers or directors), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments
to or from any such officer, director, employee or affiliate or, to the knowledge of the Company or any of its Subsidiaries, any
corporation, partnership, trust or other Person in which any such officer, director, employee or affiliate has a substantial interest
or is an employee, officer, director, trustee or partner.

 

(o)          Equity
Capitalization. As of the date hereof, the authorized capital stock of the Company consists of (i) 250,000,000 shares of Common
Stock, of which 25,675,044 are issued and outstanding and 12,750,000 shares are reserved for issuance pursuant to Convertible Securities
(as defined below) (other than the Preferred Stock and the Warrants) and (ii) 5,000,000 shares of preferred stock, none of which
are issued and outstanding. No shares of Common Stock are held in treasury. All of such outstanding shares are duly authorized
and have been, or upon issuance will be, validly issued and are fully paid and non-assessable. 2,519,297 shares of the Company’s
issued and outstanding Common Stock on the date hereof are owned by Persons who are “affiliates” (as defined in Rule
405 of the 1933 Act and calculated based on the assumption that only officers, directors and holders of at least 10% of the Company’s
issued and outstanding Common Stock are “affiliates” without conceding that any such Persons are “affiliates”
for purposes of federal securities laws) of the Company or any of its Subsidiaries. Except as disclosed on Schedule 3(o),
to the Company’s knowledge, no Person owns 10% or more of the Company’s issued and outstanding shares of Common Stock
(calculated based on the assumption that all Convertible Securities, whether or not presently exercisable or convertible, have
been fully exercised or converted (as the case may be) taking account of any limitations on exercise or conversion (including
“blockers”) contained therein without conceding that such identified Person is a 10% stockholder for purposes of federal
securities laws). (i) None of the Company’s or any Subsidiary’s capital stock is subject to preemptive rights or any
other similar rights or any liens or encumbrances suffered or permitted by the Company or any Subsidiary; (ii) except as disclosed
in the SEC Documents, there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock of the
Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to issue additional capital stock of the Company or any of its Subsidiaries or options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, or exercisable or exchangeable for, any capital stock of the Company or any of its Subsidiaries; (iii) except as disclosed
in the SEC Documents, there are no outstanding debt securities, notes, credit agreements, credit facilities or other agreements,
documents or instruments evidencing Indebtedness of the Company or any of its Subsidiaries or by which the Company or any of its
Subsidiaries is or may become bound; (iv) except as disclosed in the SEC Documents, there are no financing statements securing
obligations in any amounts filed in connection with the Company or any of its Subsidiaries; (v) except as disclosed in the SEC
Documents, there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register
the sale of any of their securities under the 1933 Act; (vi) there are no outstanding securities or instruments of the Company
or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any
of its Subsidiaries; (vii) except as disclosed in the SEC Documents, there are no securities or instruments containing anti-dilution
or similar provisions that will be triggered by the issuance of the Securities; (viii) neither the Company nor any Subsidiary has
any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement; and (ix) neither
the Company nor any of its Subsidiaries have any liabilities or obligations required to be disclosed in the SEC Documents which
are not so disclosed in the SEC Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries’
respective businesses and which, individually or in the aggregate, do not or could not have a Material Adverse Effect. The Company
has furnished to the Placement Agent true, correct and complete copies of the Company’s Articles of Incorporation, as amended
and as in effect on the date hereof (the “Articles of Incorporation”), and the Company’s bylaws, as amended
and as in effect on the date hereof (the “Bylaws”), and the terms of all Convertible Securities and the material
rights of the holders thereof. “Convertible Securities” means any capital stock, note, debenture or other security
of the Company or any of its Subsidiaries that is, or may become, at any time and under any circumstances directly or indirectly
convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any capital stock,
note, debenture or other security of the Company (including, without limitation, Common Stock) or any of its Subsidiaries.

 

    	6

    	 

    

 

 

(p)          Indebtedness
and Other Contracts. Neither the Company nor any of its Subsidiaries (i) except as disclosed in the SEC Documents, has any
outstanding Indebtedness (as defined below), (ii) is a party to any contract, agreement or instrument, the violation of which,
or default under which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected to result
in a Material Adverse Effect, (iii) except as disclosed in the SEC Documents, is in violation of any term of, or in default under,
any contract, agreement or instrument relating to any Indebtedness, except where such violations and defaults would not result,
individually or in the aggregate, in a Material Adverse Effect, or (iv) except as disclosed in the SEC Documents, is a party to
any contract, agreement or instrument relating to any Indebtedness, the performance of which, in the judgment of the Company’s
officers, has or is expected to have a Material Adverse Effect. (x) “Indebtedness” of any Person means, without
duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase
price of property or services (including, without limitation, “capital leases” in accordance with generally accepted
accounting principles) (other than trade payables entered into in the ordinary course of business), (C) all reimbursement or payment
obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes,
bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property,
assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or
incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even
though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or
sale of such property), (F) all monetary obligations under any leasing or similar arrangement which, in connection with generally
accepted accounting principles, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all
indebtedness referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness has an existing
right, contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon
or in any property or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such
assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations in
respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through (G) above; (y) “Contingent
Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect
to any indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring
such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will
be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will
be protected (in whole or in part) against loss with respect thereto; and (z) “Person” means an individual,
a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other
entity and a government or any department or agency thereof.

 

(q)          Absence
of Litigation. Except as disclosed in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before
or by the Principal Market, any court, public board, government agency, self-regulatory organization or body pending or, to the
knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries, the Common Stock or any of the
Company’s or its Subsidiaries’ executive officers or directors which is outside of the ordinary course of business
or individually or in the aggregate material to the Company or any of its Subsidiaries. There has not been, and to the knowledge
of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company, any of its Subsidiaries
or any current or former director or executive officer of the Company or any of its Subsidiaries. The SEC has not issued any active
stop order or other order suspending the effectiveness of any registration statement filed by the Company under the 1933 Act or
the 1934 Act, including, without limitation, the Registration Statement.

 

    	7

    	 

    

 

 

(r)          Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or
applied for, and neither the Company nor any such Subsidiary has any reason to believe that it will be unable to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.

 

(s)          Employee
Relations. Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or employs any
member of a union. The Company believes that its and its Subsidiaries’ relations with their respective employees are good.
No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee of the Company or any of
its Subsidiaries has notified the Company or any such Subsidiary that such officer intends to leave the Company or any such Subsidiary
or otherwise terminate such officer’s employment with the Company or any such Subsidiary. To the knowledge of the Company,
no executive officer or other key employee of the Company or any of its Subsidiaries is, or is now expected to be, in violation
of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition
agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each such executive
officer or other key employee (as the case may be) does not subject the Company or any of its Subsidiaries to any liability with
respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all federal, state, local and
foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment
and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be
expected to result in a Material Adverse Effect.

 

(t)          Title.
The Company and its Subsidiaries have good and marketable title in fee simple to all real property, and have good and marketable
title to all personal property, owned by them which is material to the business of the Company and its Subsidiaries, in each case,
free and clear of all liens, encumbrances and defects except as disclosed in the Registration Statement and such as do not materially
affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company
and any of its Subsidiaries. Any real property and facilities held under lease by the Company or any of its Subsidiaries are held
by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use
made and proposed to be made of such property and buildings by the Company or any of its Subsidiaries.

 

(u)          Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names,
service marks, service mark registrations, service names, patents, patent rights, copyrights, original works, inventions, licenses,
approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and registrations
therefor (“Intellectual Property Rights”) necessary to conduct their respective businesses as now conducted
and as presently proposed to be conducted. None of the Company’s or its Subsidiaries’ Intellectual Property Rights
have expired, terminated or been abandoned, or are expected to expire, terminate or be abandoned, within two (2) years from the
date of this Agreement. The Company has no knowledge of any infringement by the Company or any of its Subsidiaries of Intellectual
Property Rights of others. There is no claim, action or proceeding being made or brought, or to the knowledge of the Company or
any of its Subsidiaries, being threatened, against the Company or any of its Subsidiaries regarding their Intellectual Property
Rights. The Company is not aware of any facts or circumstances which might give rise to any of the foregoing infringements or claims,
actions or proceedings. The Company and each of its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their Intellectual Property Rights, except where failure to take such measures would not, either
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

(v)         Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with all Environmental Laws (as defined below), (ii) have received
all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where, in each of the foregoing
clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a
Material Adverse Effect. “Environmental Laws” means all federal, state, local or foreign laws relating to pollution
or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land
surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases
of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

    	8

    	 

    

 

 

(w)          Subsidiary
Rights. The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by applicable
law) to receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company or such Subsidiary.

 

(x)          Tax
Status. Except for occurrences that would not, either individually or in the aggregate, reasonably be expected to result in
a Material Adverse Effect, the Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state
income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably
adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers
of the Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner as to qualify
as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as amended.

 

(y)          Internal
Accounting and Disclosure Controls. The Company and each of its Subsidiaries maintains internal control over financial reporting
(as such term is defined in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles, including that (i) transactions are executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally
accepted accounting principles and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities
is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability
for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action
is taken with respect to any difference. The Company maintains disclosure controls and procedures (as such term is defined in Rule
13a-15(e) under the 1934 Act) that are effective in ensuring that information required to be disclosed by the Company in the reports
that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified
in the rules and forms of the SEC, including, without limitation, controls and procedures designed to ensure that information required
to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to the
Company’s management, including its principal executive officer or officers and its principal financial officer or officers,
as appropriate, to allow timely decisions regarding required disclosure. Neither the Company nor any of its Subsidiaries has received
any notice or correspondence from any accountant or other Person relating to any potential material weakness or significant deficiency
in any part of the internal controls over financial reporting of the Company or any of its Subsidiaries, that has not been cured
or otherwise resolved prior to the date hereof. There are no material disagreements presently existing, or reasonably anticipated
by the Company to arise, between the accountants and lawyers formerly or presently employed by the Company.

 

(z)          Off
Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries
and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its 1934 Act filings
and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

(aa)         Investment
Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an “investment company,”
an affiliate of an “investment company,” a company controlled by an “investment company” or an “affiliated
person” of, or “promoter” or “principal underwriter” for, an “investment company” as
such terms are defined in the Investment Company Act of 1940, as amended.

 

    	9

    	 

    

 

 

(bb)         Manipulation
of Price. Neither the Company nor any of its Subsidiaries has, and, to the knowledge of the Company, no Person acting on their
behalf has, directly or indirectly, (i) taken any action designed to cause or to result in the stabilization or manipulation of
the price of any security of the Company or any of its Subsidiaries to facilitate the sale or resale of any of the Securities,
(ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities (other than the Placement
Agent), or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of
the Company or any of its Subsidiaries.

 

(cc)         U.S.
Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and so long as any
of the Preferred Stock remains outstanding or Warrants remain unexercised, shall become, a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company and each Subsidiary shall so
certify upon any Investor’s request.

 

(dd)         Transfer
Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be
paid in connection with the issuance, sale and transfer of the Securities to be sold to each Investor hereunder will be, or will
have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

 

(ee)         Bank
Holding Company Act. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act of 1956, as
amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the “Federal
Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly or indirectly, five
percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total
equity of a bank or any equity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any
of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any entity that
is subject to the BHCA and to regulation by the Federal Reserve.

 

(ff)         Shell
Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

(gg)         Public
Utility Holding Act. Neither the Company nor any of its Subsidiaries is a “holding company,” or an “affiliate”
of a “holding company,” as such terms are defined in the Public Utility Holding Act of 2005.

 

(hh)         Federal
Power Act. Neither the Company nor any of its Subsidiaries is subject to regulation as a “public utility” under
the Federal Power Act, as amended.

 

(ii)         Fixtures
and Equipment. Each of the Company and its Subsidiaries (as applicable) has good title to, or a valid leasehold interest in,
the tangible personal property, equipment, improvements, fixtures, and other personal property and appurtenances that are used
by the Company or its Subsidiary in connection with the conduct of its business (the “Fixtures and Equipment”).
Except as disclosed in the SEC Documents, the Fixtures and Equipment are structurally sound, are in good operating condition and
repair, are adequate for the uses to which they are being put, are not in need of maintenance or repairs except for ordinary, routine
maintenance and repairs and are sufficient for the conduct of the Company’s and/or its Subsidiaries’ businesses (as
applicable) in the manner as conducted prior to the Closing.

 

(jj)         Illegal
or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to the Company’s
knowledge (after reasonable inquiry of its executive officers and directors), any of the officers, directors, employees, agents
or other representatives of the Company or any of its Subsidiaries or any other business entity or enterprise with which the Company
or any Subsidiary is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution
or gift of money, property, or services, whether or not in contravention of applicable law, (a) as a kickback or bribe to any Person
or (b) to any political organization, or the holder of or any aspirant to any elective or appointive public office except for personal
political contributions not involving the direct or indirect use of funds of the Company or any of its Subsidiaries.

 

    	10

    	 

    

 

 

(kk)         Money
Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act
of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without limitation, the
laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including,
without limitation, (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions
With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations
contained in 31 CFR, Subtitle B, Chapter V.

 

(ll)         Securities
Law Filings. A registration statement on Form F-1 (File No. 333-195166) (the “Registration Statement”) in
respect of the Securities has been filed with the Commission; prior to the Closing, the Registration Statement and any post-effective
amendment thereto, each in the form heretofore delivered to the Placement Agent, has been declared effective by the Commission
in such form; other than a registration statement, if any, increasing the size of the Offering (a “Rule 462(b) Registration
Statement”), filed pursuant to Rule 462(b) under the 1933 Act, which became effective upon filing, no other document
with respect to the Registration Statement has heretofore been filed with the Commission; and no stop order suspending the effectiveness
of the Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration Statement, if any, has been
issued and no proceeding for that purpose has been initiated or threatened by the Commission (any preliminary prospectus included
in the Registration Statement or filed with the Commission pursuant to Rule 424(a) under the 1933 Act is hereinafter called a “Preliminary
Prospectus”; the various parts of the Registration Statement and the Rule 462(b) Registration Statement, if any, including
all exhibits thereto and including the information contained in the form of final prospectus filed with the Commission pursuant
to Rule 424(b) under the 1933 Act and deemed by virtue of Rule 430A under the 1933 Act to be part of the Registration Statement
at the time it was declared effective, each as amended at the time such part of the Registration Statement became effective or
such part of the Rule 462(b) Registration Statement, if any, became or hereafter becomes effective, are hereinafter collectively
called the “Registration Statement”; the final prospectus, in the form first filed pursuant to Rule 424(b) under
the 1933 Act, is hereinafter called the “Prospectus”. Any reference in this Agreement to the Registration Statement,
the Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein
(the “Incorporated Documents”), which were or are filed under the 1934 Act, at any given time, as the case may
be.

 

(mm)         Assurances.
The Registration Statement, as amended, (and any further documents to be filed with the Commission) contains all exhibits and schedules
as required by the 1933 Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became
effective, complied in all material respects with the 1933 Act and the applicable rules and regulations thereunder (“Rules
and Regulations”) and did not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading. Each of the Prospectus and the Preliminary Prospectus,
as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading. The Incorporated Documents, when they were filed with the Commission, conformed in all material respects
to the requirements of the 1934 Act and the applicable rules and regulations promulgated thereunder, and none of such documents,
when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact
necessary to make the statements therein (with respect to Incorporated Documents incorporated by reference in the Registration
Statement), in light of the circumstances under which they were made not misleading. No post-effective amendment to the Registration
Statement reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental
change in the information set forth therein is required to be filed with the Commission. Except for this Agreement, the Certificate
of Designation and the form of Warrant there are no documents required to be filed with the Commission in connection with the transaction
contemplated hereby that (x) have not been filed as required pursuant to the 1933 Act or (y) will not be filed within the requisite
time period. Except for this Agreement, there are no contracts or other documents required to be described in the Prospectus, or
to be filed as exhibits or schedules to the Registration Statement, which have not been described or filed as required. The Company
is eligible to use free writing prospectuses in connection with the Offering pursuant to Rules 164 and 433 under the 1933 Act.
Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the 1933 Act has been, or will be,
filed with the Commission in accordance with the requirements of the 1933 Act and the applicable rules and regulations of the Commission
thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the
1933 Act or that was prepared by or behalf of or used by the Company complies or will comply in all material respects with the
requirements of the 1933 Act and the Rules and Regulations. 

 

    	11

    	 

    

 

 

(nn)         Offering
Materials. Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior
to the Closing Date, any offering material in connection with the Offering.

 

(oo)         Certificates.
Any certificate signed by an officer of the Company and delivered to the Placement Agent or to counsel for the Placement Agent
shall be deemed to be a representation and warranty by the Company to the Placement Agent and Investors as to the matters set forth
therein.

 

(pp)         Statistical
or Market-Related Data. Any statistical, industry-related and market-related data included or incorporated by reference in
the Registration Statement, the Prospectus or the Preliminary Prospectus, are based on or derived from sources that the Company
reasonably and in good faith believes to be reliable and accurate, and such data agree with the sources from which they are derived.

 

(qq)         FINRA
Affiliations. There are no affiliations with any FINRA member firm among the Company’s officers, directors or, to the
knowledge of the Company, any five percent (5%) or greater stockholder of the Company.

 

(rr)         Disclosure.
All disclosure provided to the Placement Agent regarding the Company and its Subsidiaries, their businesses and the transactions
contemplated hereby, including the schedules to this Agreement, furnished by or on behalf of the Company or any of its Subsidiaries
is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading. Each press release issued by the Company or any of its Subsidiaries during the twelve (12) months preceding the
date of this Agreement did not at the time of release contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they are made, not misleading. No event or circumstance has occurred or information exists with respect to the Company or
any of its Subsidiaries or its or their business, properties, liabilities, prospects, operations (including results thereof) or
conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public disclosure at or before the
date hereof or announcement by the Company but which has not been so publicly disclosed.

 

(ss)         Acknowledgment
Regarding Purchase of Securities. The Company acknowledges and agrees that each Investor is acting solely in the capacity of
an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby
and that no Investor is (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate” (as
defined in Rule 144 promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule 144”)) of the
Company or any of its Subsidiaries or (iii) to its knowledge, a “beneficial owner” of more than 10% of the shares of
Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further acknowledges that no Investor is acting
as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to the
Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by an Investor or any of its representatives
or agents in connection with any of the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental
to such Investor’s purchase of the Securities.

 

(tt)         Placement
Agent’s Fees. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory
fees, or brokers’ commissions (other than for Persons engaged by any Investor or its investment advisor) relating to or arising
out of the transactions contemplated hereby. Other than the Placement Agent, neither the Company nor any of its Subsidiaries has
engaged any placement agent or other agent in connection with the offer or sale of the Securities.

 

(uu)         No
Integrated Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting on their behalf
has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would cause this offering of the Securities to require approval of stockholders of the Company under any applicable stockholder
approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system
on which any of the securities of the Company are listed or designated for quotation. None of the Company, its Subsidiaries, their
affiliates nor any Person acting on their behalf will take any action or steps that would cause the offering of any of the Securities
to be integrated with other offerings of securities of the Company.

 

    	12

    	 

    

 

 

(vv)         Reliance.
The Company acknowledges that the Placement Agent and each Investor will rely upon the accuracy and truthfulness of the foregoing
representations and warranties and hereby consents to such reliance.

 

3.          Delivery
and Payment. The Closing shall occur at such place as shall be agreed upon by the Placement Agent
and the Company. In the absence of an agreement to the contrary, the Closing shall take place at the offices of Schiff Hardin LLP,
901 K Street, NW, Suite 700, Washington, DC 20001. Subject to the terms and conditions hereof, at the Closing payment of the purchase
price for the Securities sold on such Closing Date (net of any commissions or reimbursements payable by the Company pursuant to
this Agreement) shall be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall be
registered in such name or names and shall be in such denominations, as the Placement Agent may request at least two business days
before the time of purchase (as defined below). Deliveries of the documents with respect to the purchase of the Securities, if
any, shall be made at the offices of Schiff Hardin, LLP, 901 K Street, NW, Suite 700, Washington, DC 20001 on the Closing Date.
On the Closing Date, certificates representing the Preferred Stock and Warrants to which the Closing relates shall be delivered
to the Placement Agent or through such other means as the parties may hereafter agree. All actions taken at the Closing shall be
deemed to have occurred simultaneously.

 

4.          Certain
Covenants and Agreements of the Company. The Company further covenants to the Placement Agent
and to each of the Investors as follows: 

 

(a)          Registration
Matters. To prepare the Prospectus in a form approved by the Placement Agent and to file such Prospectus pursuant to Rule 424(b)
under the 1933 Act not later than the earlier to occur of (x) the Commission’s close of business on the second business day
following the execution and delivery of this Agreement and (y) 8:30 a.m. (New York time) on the Closing Date, or, if applicable,
such earlier time as may be required by Rule 430A(a)(3) under the 1933 Act; to make no further amendment or any supplement to the
Registration Statement or the Prospectus prior to the Closing Date which shall be disapproved by the Placement Agent promptly after
reasonable notice thereof; to advise the Placement Agent, promptly after it receives notice thereof, of the time when any amendment
to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed
and to furnish the Placement Agent with copies thereof; if eligible for such use, to file promptly all material required to be
filed by the Company with the Commission pursuant to Rule 433(d) under the 1933 Act; to advise the Placement Agent, promptly after
it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use
of any Preliminary Prospectus or Prospectus in respect of the Securities, of the suspension of the qualification of the Securities
for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any request
by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information;
and, in the event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus
or Prospectus in respect of the Securities or suspending any such qualification, to promptly use its best efforts to obtain the
withdrawal of such order.

 

(b)          Qualification.
Promptly from time to time to take such action as the Placement Agent may reasonably request to qualify the Securities for offering
and sale under the securities laws of such jurisdictions as the Placement Agent may request and to comply with such laws so as
to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete the Offering.
Without limiting any other obligation of the Company under this Agreement, the Company shall timely make all filings and reports
relating to the offer and sale of the Securities required under all applicable securities laws (including, without limitation,
all applicable federal securities laws and all applicable “Blue Sky” laws), and the Company shall comply in all material
respects with all applicable federal, foreign, state and local laws, statutes, rules, regulations and the like relating to the
offering and sale of the Securities to the Investors.

 

    	13

    	 

    

 

 

(c)          Listing.
The Company shall promptly secure the listing or designation for quotation (as the case may be) of all of the Conversion Shares
and Warrant Shares upon each trading market and national securities exchange and automated quotation system, if any, upon which
the Common Stock is then listed or designated for quotation (as the case may be) (so that all such Conversion Shares and Warrant
Shares may be traded on the foregoing) (but in no event later than the Closing Date) and shall maintain such listing or designation
for quotation (as the case may be) of all the Conversion Shares and Warrant Shares on such national securities exchange or automated
quotation system. The Company shall maintain the Common Stock’s listing or designation for quotation (as the case may be)
on the Principal Market, The New York Stock Exchange, the NYSE MKT, the Nasdaq Global Select Market or the Nasdaq Global Market
(each, an “Eligible Market”). Neither the Company nor any of its Subsidiaries shall take any action which could
be reasonably expected to result in the delisting or suspension of the Common Stock on an Eligible Market. The Company shall pay
all fees and expenses in connection with satisfying its obligations under this section.

 

(d)          Amendments
and Supplements to a Prospectus Supplement and Other Matters. The Company will comply with the 1933 Act and the 1934 Act, and
the rules and regulations of the Commission thereunder, so as to permit the completion of the issuance and sale of the Securities
as contemplated in this Agreement and the Prospectus. If during the period in which a prospectus is required by law to be delivered
in connection with the issuance and sale of Securities contemplated by the Prospectus (the “Prospectus Delivery Period”),
any event shall occur as a result of which, in the judgment of the Company or in the opinion of the Placement Agent or counsel
for the Placement Agent, it becomes necessary to amend or supplement the Registration Statement or Prospectus in order to make
the statements therein, in the light of the circumstances under which they were made, as the case may be, not misleading, or if
it is necessary at any time to amend or supplement the Registration Statement or Prospectus to comply with any law, the Company
will promptly prepare and file with the Commission, and furnish at its own expense to the Placement Agent, an appropriate amendment
to the Registration Statement or supplement to the Registration Statement or Prospectus that is necessary in order to make the
statements in the Registration Statement and Prospectus as so amended or supplemented, in the light of the circumstances under
which they were made, as the case may be, not misleading, or so that the Registration Statement or Prospectus, as so amended or
supplemented, will comply with law. Before amending the Registration Statement or supplementing the Prospectus in connection with
the Offering, the Company will furnish the Placement Agent with a copy of such proposed amendment or supplement and will not file
any such amendment or supplement to which the Placement Agent reasonably objects.

 

(e)          Free
Writing Prospectus. The Company covenants that it will not, unless it provides notice to the Placement Agent, make any offer
relating to the Securities that would constitute an a “free writing prospectus” (as defined in Rule 405 of the
1933 Securities Act) required to be filed by the Company with the Commission or retained by the Company under Rule 433 of the Securities
Act (a “Permitted Free Writing Prospectus”).

 

(f)          Transfer
Agent. The Company will maintain, at its expense, a registrar and transfer agent for the Preferred Stock and Warrants.

 

(g)          Earnings
Statement. To make generally available to its securityholders (which may be satisfied by filing with the Commission's Electronic
Data Gathering, Analysis and Retrieval System (“EDGAR”)) as soon as practicable, but in any event not later
than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the 1933 Act), an earnings
statement of the Company complying with Section 11(a) of the 1933 Act and the Rules and Regulations (including, at the option of
the Company, Rule 158).

 

(h)          Reporting
Status. Until the date on which none of the Warrants is outstanding (the “Reporting Period”), the Company
shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its
status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would
no longer require or otherwise permit such termination.

 

(i)          Reservation
of Shares. So long as any of the shares of Preferred Stock or Warrants remain outstanding, the Company shall take all action
necessary to at all times have authorized, and reserved for the purpose of issuance, no less than 133% of (i) the maximum number
of shares of Common Stock then issuable upon conversion of all the shares of Preferred Stock and without regard to any limitations
on the conversion of any of the Preferred Stock set forth in the Certificate of Designation) and (ii) the maximum number of Warrant
Shares issuable upon exercise or exchange of all the Warrants (without regard to any limitations on the exercise of the Warrants
set forth therein).

 

    	14

    	 

    

 

 

(j)          Conduct
of Business. The business of the Company and its Subsidiaries shall not be conducted in violation of any law, ordinance or
regulation of any governmental entity, except where such violations would not result, either individually or in the aggregate,
in a Material Adverse Effect. 

 

(k)          Passive
Foreign Investment Company. The Company shall conduct its business in such a manner as will ensure that the Company will not
be deemed to constitute a passive foreign investment company within the meaning of Section 1297 of the U.S. Internal Revenue Code
of 1986, as amended.

 

(l)          Corporate
Existence. So long as any shares of Preferred Stock or Warrants are outstanding, the Company shall not be party to any Fundamental
Transaction (as defined in the Warrants) unless the Company is in compliance with the applicable provisions governing Fundamental
Transactions set forth in the Warrants.

 

(m)          No
Manipulation of Price. The Company will not take, directly or indirectly, any action designed to cause or result
in, or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any
securities of the Company in violation of the 1934 Act or rules thereunder.

 

(n)          Additional
Registration Statements. The Company agrees that for the period commencing on the date hereof and ending on the date immediately
following the 90th day after the Closing, the Company shall not file any registration statement under the 1933 Act relating
to any securities of the Company, without the prior written consent of the Required Holders (as defined in the Warrants).

 

(o)          Additional
Issuance of Securities. The Company agrees that for the period commencing on the date hereof and ending on the date immediately
following the 180th day after the Closing (the “Restricted Period”), neither the Company nor any
of its Subsidiaries shall directly or indirectly issue, offer, sell, grant any option or right to purchase, or otherwise dispose
of (or announce any issuance, offer, sale, grant of any option or right to purchase or other disposition of) any equity security
or any equity-linked or related security (including, without limitation, any “equity security” (as that term is defined
under Rule 405 promulgated under the 1933 Act), any Convertible Securities, any debt, any preferred stock or any purchase rights
(any such issuance, offer, sale, grant, disposition or announcement (whether occurring during the Restricted Period or at any time
thereafter) is referred to as a “Subsequent Placement”) without the prior written consent of the Required Holders
(as defined in the Warrants). Notwithstanding the foregoing, this Section 4(o) shall not apply in respect of the issuance of any
Excluded Securities (as defined in the Certificate of Designation).

 

(p)          Special
Restrictions on Transactions. Until the two (2) year anniversary of the Closing, the Company and each Subsidiary shall be prohibited
from effecting or entering into an agreement to effect any Subsequent Placement involving a Variable Rate Transaction without the
prior written consent of the Required Holders. “Variable Rate Transaction” means a transaction in which the
Company or any Subsidiary (i) issues or sells any Convertible Securities either (A) at a conversion, exercise or exchange rate
or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of Common Stock at any
time after the initial issuance of such Convertible Securities, or (B) with a conversion, exercise or exchange price that is subject
to being reset at some future date after the initial issuance of such Convertible Securities or upon the occurrence of specified
or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock, other than
pursuant to a customary “weighted average” anti-dilution provision or (ii) enters into any agreement (including, without
limitation, an “equity line of credit” or an “at the market offering”) whereby the Company or any Subsidiary
may sell securities at a future determined price (other than standard and customary “preemptive” or “participation”
rights). Each Investor shall be entitled to obtain injunctive relief against the Company and its Subsidiaries (as applicable) to
preclude any such issuance, which remedy shall be in addition to any right to collect damages.

 

(q)          Material
Information. From and after the time which the Registration Statement is declared effective by the SEC, the Company shall have
publicly disclosed all material, non-public information (if any) regarding the Company or any of its Subsidiaries delivered to
any of the Investors by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents
in connection with the transactions contemplated by the Transaction Documents.

 

(r)          Restriction
on Redemption and Cash Dividends. So long as any shares of Preferred Stock are outstanding, the Company shall not, directly
or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities of the Company without the prior
express written consent of the Investors.

 

    	15

    	 

    

 

 

(s)          Acknowledgment.
The Company acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit and use of the Board
of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement Agent's
prior written consent.

 

5.          Conditions
of the Obligations of the Placement Agent. The obligations of the Placement Agent hereunder,
and the obligation of each Investor to purchase Preferred Stock and Warrants from the Company, shall be subject to the accuracy
of each representation and warranty on the part of the Company set forth in Section 2 hereof, in each case as of the date hereof
and as of the Closing Date as though originally made on the Closing Date, to the timely performance by each of the Company of its
covenants and other obligations hereunder on and as of such dates, and to each of the following additional conditions: 

 

(a)          Compliance
with Registration Requirements; No Stop Order; No Objection from FINRA. The Prospectus (in accordance with Rule 424(b))
and any “free writing prospectus” (as defined in Rule 405 of the 1933 Act), if any, shall have been duly filed
with the Commission, as appropriate; no stop order suspending the effectiveness of the Registration Statement or any part thereof
shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order preventing
or suspending the use of the Prospectus shall have been issued and no proceeding for that purpose shall have been initiated or
threatened by the Commission; no order having the effect of ceasing or suspending the issuance or sale of the Securities or any
other securities of the Company shall have been issued by any securities commission, securities regulatory authority or stock exchange
and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated
by any securities commission, securities regulatory authority or stock exchange; all requests for additional information on the
part of the Commission shall have been complied with; and FINRA shall have raised no objection to the fairness and reasonableness
of the placement terms and arrangements.

 

(b)          Corporate
Proceedings. All corporate proceedings and other legal matters in connection with this Agreement, the Registration Statement
and the Prospectus, and the registration, sale and delivery of the Securities, shall have been completed or resolved in a manner
reasonably satisfactory to the Placement Agent's counsel, and such counsel shall have been furnished with such papers and information
as it may reasonably have requested to enable such counsel to pass upon the matters referred to in this Section 5. The Company
shall have filed the Certificate of Designation with the Secretary of State (or equivalent thereof) of the Company’s jurisdiction
of incorporation and the Certificate of Designation shall be in full force and effect.

 

(c)          No
Material Adverse Effect. Subsequent to the execution and delivery of this Agreement and prior to the Closing Date, in the Placement
Agent's sole and reasonable judgment after consultation with the Company, there shall not have occurred any event that has resulted
in or reasonably could result in a Material Adverse Effect.

 

(d)           Opinions
of Counsel for the Company.

 

(i)          The
Placement Agent shall have received from outside counsel to the Company such counsel’s written opinion, addressed to the
Placement Agent and the Investors dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement
Agent, for the benefit of the Placement Agent and each of the Investors (the opinion shall include a statement that each Investor
may rely upon the opinion).

 

(ii)         The
Placement Agent shall receive an opinion from tax counsel to the Company dated as of the Closing Date, in form and substance reasonably
satisfactory to the Placement Agent, to the effect that the descriptions of the tax consequences of investing in the Offering set
forth in the Registration Statement, Preliminary Prospectus and Prospectus are true, complete and correct in all material respects,
in form and substance reasonably satisfactory to the Placement Agent, for the benefit of the Placement Agent and each of the Investors
(the opinion shall include a statement that each Investor may rely upon the opinion).

 

    	16

    	 

    

 

 

(iii)        The
Placement Agent shall receive an opinion from maritime counsel to the Company dated as of the Closing Date, in form and substance
reasonably satisfactory to the Placement Agent, for the benefit of the Placement Agent and each of the Investors (the opinion shall
include a statement that each Investor may rely upon the opinion).

 

(e)          Officers’
Certificate. The Placement Agent shall have received on the Closing Date a certificate of the Company, dated as of the Closing
Date, signed by the Chief Executive Officer and Chief Financial Officer of the Company, for the benefit of the Placement Agent
and each of the Investors, that:

 

(i)          Each
representation and warranty of the Company in this Agreement is true and correct as if originally made on and as of the Closing
Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied
at or prior to the Closing Date;

 

(ii)         No
stop order suspending the effectiveness of the Registration Statement or the use of the Preliminary Prospectus or Prospectus has
been issued and no proceedings for that purpose have been instituted or are pending or, to the Company’s knowledge, threatened
under the 1933 Act; no order having the effect of ceasing or suspending the issuance or sale of the Securities or any other securities
of the Company has been issued by any securities commission, securities regulatory authority or stock exchange and no proceedings
for that purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission,
securities regulatory authority or stock exchange;

 

(iii)        When
the Registration Statement became effective and at the time of sale of the Securities, the Registration Statement, including the
documents incorporated by reference therein, when such documents became effective or were filed with the Commission, contained
all material information required to be included therein by the 1933 Act and the 1934 Act and the applicable rules and regulations
of the Commission thereunder, as the case may be, and in all material respects conformed to the requirements of the 1933 Act and
the 1934 Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and the Registration Statement,
including the documents incorporated by reference therein, did not and do not include any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading and, since the effective date of the Registration Statement, there has occurred no event
required by the 1933 Act and the Rules and Regulations of the Commission thereunder to be set forth in any filings under the 1934
Act which has not been so set forth; and

 

(iv)        Subsequent
to the date of the Prospectus, there has not been: (a) any event that would result in a Material Adverse Effect; (b) any transaction
that is material to the Company and the Subsidiaries taken as a whole, except transactions entered into in the ordinary course
of business; (c) any obligation, direct or contingent, that is material to the Company and the Subsidiaries taken as a whole, incurred
by the Company or any Subsidiary, except obligations incurred in the ordinary course of business; (d) any material change in the
capital stock (except changes thereto resulting from the exercise of outstanding stock options or warrants and the creation and
issuance of the Preferred Stock and Warrants) or outstanding indebtedness of the Company or any Subsidiary; (e) any dividend or
distribution of any kind declared, paid or made on the capital stock of the Company; or (f) any loss or damage (whether or not
insured) to the property of the Company or any Subsidiary which has been sustained or will have been sustained which has resulted
in or could reasonably result in has a Material Adverse Effect.

 

(f)          Secretary’s
Certificate. The Placement Agent shall have received on the Closing Date, for the benefit of the Placement Agent and each of
the Investors, a certificate of the Company, dated as of the Closing Date, in the form reasonably acceptable to Placement Agent,
executed by the Secretary of the Company and dated as of the Closing Date, as to (i) the resolutions adopted by the Company’s
board of directors in a form reasonably acceptable to Placement Agent, (ii) Articles of Incorporation, including, without limitation,
the Certificate of Designation, and (iii) the Bylaws of the Company, in each case, as in effect at the Closing.

 

(g)          Good
Standing. The Company shall have delivered to the Placement Agent a certificate evidencing the formation and good standing
of the Company in its jurisdiction of formation issued by the Secretary of State (or comparable office) of such jurisdiction of
formation as of a date within ten (10) days of the Closing Date.

 

    	17

    	 

    

 

 

(h)          Stock
Exchange Listing. The Conversion Shares and Warrant Shares underlying the Preferred Stock and Warrants to be sold at the Closing
shall have been approved for listing on the Principal Market.

 

(i)          Additional
Documents. On or before the Closing Date, the Placement Agent and counsel for the Placement Agent shall have received such
information and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of
the Securities as contemplated in this Agreement, or in order to evidence the accuracy of any of the representations and warranties,
or the satisfaction of any of the conditions or agreements, contained in this Agreement.

 

If any condition specified
in this Section 5 is not satisfied when and as required to be satisfied, no Investor shall have any obligation to purchase any
Securities and this Agreement may be terminated by the Placement Agent by notice to the Company at any time on or prior to the
Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 7,
8 and 9 shall at all times be effective and shall survive such termination. 

 

6.          Payment
of Expenses; Tail Financing.

 

(a)          The
Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance of its obligations
hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident
to the issuance, delivery and qualification of the Securities (including all printing and engraving costs); (ii) all fees and expenses
of the registrar and transfer agent of any of the Securities; (iii) all necessary issue, transfer and other stamp taxes in connection
with the issuance and sale of the Securities; (iv) all fees and expenses of the Company’s counsel, independent public or
certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing,
filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents
and certificates of experts), the Preliminary Prospectus and Prospectus, and all amendments and supplements thereto, and this Agreement;
(vi) all filing fees and expenses incurred by the Company or the Placement Agent in connection with qualifying or registering (or
obtaining exemptions from the qualification or registration of) all or any part of the Securities for offer and sale under the
state securities or blue sky laws or the securities laws of any other country; (vii) if applicable, the filing fees incident to
the review and approval by FINRA of the Placement Agent's participation in the offering and sale of the Securities; (viii) the
fees and expenses associated with including the Conversion Shares and Warrant Shares on the Principal Market; (ix) all costs and
expenses incident to the travel and accommodation of the Company’s employees on the “roadshow,” if any;
and (x) all other fees, costs and expenses referred to in Part II of the Registration Statement. Additionally, the Company agrees
to reimburse Placement Agent for all documented and reasonable travel and transaction related expenses, including any road show
expenses. The Company agrees to reimburse the Placement Agent for all documented and reasonable travel and transaction related
expenses, including any road show expenses, which road show expenses shall be subject to a $5,000 maximum reimbursement amount.
The Company also agrees to reimburse the Placement Agent for all reasonable legal and diligence fees necessary to the completion
of its duties and obligations for this Agreement, up to a maximum of $50,000 (less the $25,000 advance previously made to the Placement
Agent). These expenses incurred by the Placement Agent are to be paid by the Company to the Placement Agent within 15 calendar
days of receiving written documentation of the expenses incurred irrespective whether the Offering is completed.

 

(b)          The
Placement Agent shall be entitled to fees per Section 1(g) of this Agreement with respect to any public or private offering or
other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing
or capital is provided to the Company by investors whom the Placement Agent had introduced to the Company, but excluding those
investors set forth on Annex A, if such Tail Financing is consummated at any time within the 12-month period following the Offering
contemplated by this Agreement.

 

    	18

    	 

    

 

 

 

7.          Indemnification
and Contribution. 

 

 

(a)          The
Company agrees to indemnify and hold harmless (x) the Placement Agent, its affiliates and each person controlling the Placement
Agent (within the meaning of Section 15 of the 1933 Act), and the directors, officers, agents and employees of the
Placement Agent, its affiliates and each such controlling person (the Placement Agent and each such other Person referred to in
this clause (x) is referred to herein as a “Placement Agent Indemnified Person”) and (y) each Investor and each
holder of any Securities and all of their stockholders, partners, members, officers, directors, employees and direct or indirect
investors and any of the foregoing Persons’ agents or other representatives (including, without limitation, those retained
in connection with the transactions contemplated by this Agreement) (each Investor and each other Person referred to in this clause
(y) is referred to herein as an “Investor Indemnified Person” and all Investor Indemnified Persons and all Placement
Agent Indemnified Persons are collectively referred to herein as the “Indemnified Persons”), in each case, from
and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the “Liabilities”),
and shall reimburse each Indemnified Person for all fees and expenses (including the reasonable fees and expenses of counsel for
the Indemnified Persons, except as otherwise expressly provided in this Agreement) (collectively, the “Expenses”)
and agrees to advance payment of such Expenses as they are incurred by an Indemnified Person in investigating, preparing, pursuing
or defending any actions, whether or not any Indemnified Person is a party thereto, (i) caused by, or arising out of or in connection
with, any untrue statement or alleged untrue statement of a material fact contained in any the Registration Statement, Preliminary
Prospectus or Prospectus (including any documents incorporated by reference therein) or by any omission or alleged omission to
state therein a material fact necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading (other than untrue statements or alleged untrue statements in, or omissions or alleged omissions from, information
relating to an Indemnified Person furnished in writing by or on behalf of such Indemnified Person expressly for use in the Registration
Statement) or any breach or inaccuracy of any representation, warranty, covenant or agreement made by the Company in this Agreement
or (ii) solely in the case of Placement Agent Indemnified Persons, otherwise arising out of or in connection with advice or services,
or alleged advice or services, rendered or to be rendered by any Placement Agent Indemnified Person pursuant to this Agreement,
the transactions contemplated thereby or any Placement Agent Indemnified Person's actions or inactions in connection with any such
advice, services or transactions; provided, however, that, in the case of clause (ii) only, the Company shall not be
responsible to indemnify for any Liabilities or Expenses of any Placement Agent Indemnified Person if a Court of competent jurisdiction
has issued an order finding that those Liabilities or Expenses resulted primarily from that Placement Agent Indemnified Person’s
use of any offering materials or information concerning the Company in connection with the offer or sale of the Securities in the
Offering which were not authorized for such use by the Company and which use is determined by a court of competent jurisdiction
to be the result of willful misconduct. The Company also agrees to reimburse each Indemnified Person for all Expenses as they are
incurred in connection with such Indemnified Person's enforcement of his or its rights under this Agreement. 

 

(b)          Upon
receipt by an Indemnified Person of actual notice of an action against such Indemnified Person with respect to which indemnity
may reasonably be expected to be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing;
provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any obligation or liability
which the Company may have on account of this Section 7 or otherwise to such Indemnified Person. The Company shall, if requested
by the applicable Indemnified Person, assume the defense of any such action (including the employment of counsel designated by
the applicable Indemnified Person and reasonably satisfactory to the Company). Any Indemnified Person shall have the right to employ
separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be
at the expense of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense and employ separate
counsel designated by the such Indemnified Person for the benefit of such Indemnified Person and the other Indemnified Persons
or (ii) such Indemnified Person shall have been advised that in the opinion of counsel that there is an actual or potential conflict
of interest that prevents (or makes it imprudent for) the counsel designated by such Indemnified Person and engaged by the Company
for the purpose of representing such Indemnified Person, to represent both such Indemnified Person and any other person represented
or proposed to be represented by such counsel. The Company shall not be liable for any settlement of any action effected without
its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent
of the applicable Indemnified Person, settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate
any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought
hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination
(i) includes an unconditional release of each Indemnified Person, acceptable to such Indemnified Party, from all Liabilities arising
out of such action for which indemnification or contribution may be sought hereunder and (ii) does not include a statement
as to or an admission of fault, culpability or a failure to act, by or on behalf of any Indemnified Person. The advancement, reimbursement,
indemnification and contribution obligations of the Company required hereby shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as every Liability and Expense is incurred and is due and payable, and in such
amounts as fully satisfy each and every Liability and Expense as it is incurred (and in no event later than 30 days following the
date of any invoice therefore).

 

    	19

    	 

    

 

 

(c)           In
the event that a court of competent jurisdiction makes a finding that indemnity is unavailable to an Indemnified Person, the Company
shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate
to reflect (i) the relative benefits to the Company, on the one hand, and to such Indemnified Person, on the other hand, of the
matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding clause is not permitted
by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and such Indemnified
Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate, as well as any other
relevant equitable considerations; provided that, solely with respect to the Placement Agent Indemnified Persons, in no event shall
the Company contribute less than the amount necessary to ensure that all Placement Agent Indemnified Persons, in the aggregate,
are not liable for any Liabilities and Expenses in excess of the amount of fees actually received by the Placement Agent pursuant
to this Agreement. For purposes of this paragraph, solely with respect to the Placement Agent Indemnified Persons, the relative
benefits to the Company, on the one hand, and to the Placement Agent on the other hand, of the matters contemplated by this Agreement
shall be deemed to be in the same proportion as: (a) the total value received by the Company in the transaction or transactions
that are within the scope of this Agreement, whether or not any such transaction is consummated, bears to (b) the fees paid to
the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the
meaning of Section 11(f) of the 1933 Act, as amended, shall be entitled to contribution from a party who was not guilty of fraudulent
misrepresentation.

 

(d)          The
Company also agrees that no Placement Agent Indemnified Person shall have any liability (whether direct or indirect, in contract
or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Placement Agent
Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Placement Agent Indemnified Person's
actions or inactions in connection with any such advice, services or transactions, except to the extent that a court of competent
jurisdiction has made a finding that Liabilities (and related Expenses) of the Company have resulted exclusively from such Placement
Agent Indemnified Person's gross negligence or willful misconduct in connection with any such advice, actions, inactions or services.

 

(e)          The
advancement, reimbursement, indemnity and contribution obligations of the Company set forth in this Section 7 shall apply to any
modification of this Agreement and shall remain in full force and effect regardless of any termination of this Agreement, or the
completion of any Indemnified Person's services under or in connection with this Agreement.

 

8.          Intended
Third Party Beneficiaries. It is the intent of the Company and the Placement Agent that each
Investor in the Offering shall be an intended third party beneficiary of: (i) each of the representations, warranties, covenants
and agreements made by the Company in Section 2 of this Agreement, (ii) the covenants and agreements made by the Company in Section
4 of this Agreement, (iii) the Closing deliverables addressed in Section 5 of this Agreement; and (v) covenants and agreements
made by the Company in Sections 7 through 14, in each case as if each Investor was a party to this Agreement; and the Company further
agrees that each Investor shall have right to sue the Company for damages that are suffered by the Investor in connection with
its purchase of any Securities or that arise from the Company’s breach of one or more representations, warranties, covenants
and/or agreements made by the Company and referenced in this Section 8. The Indemnified Persons referred to in Section 7 are also
intended to be intended third party beneficiaries of this Agreement.

 

9.          Survival
& Successors. Notwithstanding anything to the contrary contained in this Agreement, the Company’s
obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable pursuant to Section
1 hereof (and which are permitted to be reimbursed under FINRA Rule 5110), will survive any delivery of, and payment for, the Securities
sold hereunder and any expiration or termination of this Agreement. Furthermore, notwithstanding anything to the contrary contained
in this Agreement, the provisions of Sections 2, 4 and 6 through 14 will also survive any delivery of, and payment for, the Securities
sold hereunder, and any expiration or termination of this Agreement. The representations, warranties, covenants and agreements
shall survive the Closing the consummation of the Offering. Notwithstanding anything to the contrary contained in this Agreement,
any successor to a Placement Agent as well as any such successor’s directors, officers and any person(s) controlling such
successor, shall be entitled to the benefits of the advancement, reimbursement, indemnity and contribution provisions set forth
in Section 7 of this Agreement.

 

    	20

    	 

    

 

 

10.         Notices.
All communications hereunder shall be in writing and shall be hand delivered, faxed or e-mailed
to the parties hereto as follows:

 

If to the Placement Agent to the address
set forth above, attn: CEO

 

If to the Company:

 

FREESEAS INC.

10 Eleftheriou Venizelou Street

(Panepistimiou Ave.)

10671 Athens, Greece

Facsimile: 011-30 210 4291 010

Attention: Chief Executive Officer

 

With a copy (for informational purposes
only) to:

 

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

Facsimile: (212) 930-9725

Attention: Marc J. Ross, Esq.

 

If to any Investor, to the address, fax or e-mail provided by
such Investor to the Company or the Placement Agent from time to time in accordance with this Section 10.

 

Any party hereto may change the address
for receipt of communications by giving written notice to the others. 

 

11.         Successors.
This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the
benefit of the Indemnified Persons, and to their respective successors, and personal representative, and, except as set forth in
Section 8 of this Agreement, no other Person will have any right or obligation hereunder. 

 

12.         Partial
Unenforceability. The invalidity or unenforceability of any section, paragraph or provision of
this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any Section,
paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to
be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

 

13.         Governing
Law, Venue & Consent to Jurisdiction Provisions. This Agreement shall be deemed to have been
made and delivered in New York City in New York State and both this Agreement and the transactions contemplated hereby shall be
governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of New
York, without regard to the conflict of laws principles thereof. Each of the Placement Agent and the Company: (i) agrees that any
legal suit, action or proceeding arising out of or relating to this Agreement and/or the transactions contemplated hereby shall
be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court for the Southern
District of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding,
and (iii) irrevocably consents to the jurisdiction of the New York Supreme Court, County of New York, and the United States District
Court for the Southern District of New York in any such suit, action or proceeding. Each of the Placement Agent and the Company
further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding
in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York
and agrees that service of process upon the Company mailed by certified mail to the Company’s address shall be deemed in
every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process upon
the Placement Agent mailed by certified mail to the Placement Agent’s address shall be deemed in every respect effective
service process upon the Placement Agent, in any such suit, action or proceeding. If either party shall commence an action or proceeding
to enforce any provision of this Agreement, then without limiting any other provision of this Agreement, the prevailing party in
such action or proceeding shall be reimbursed by the other party for its reasonable attorney’s fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding. EACH PARTY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    	21

    	 

    

 

 

14.         General
Provisions. 

 

(a)          This
Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party. In the event that any signature is
delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature
page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such signature page were an original thereof.

 

(b)          This
Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition in this Agreement (express
or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit, provided, however, that
the Placement Agent may waive any condition on behalf of the Investors. Section headings in this Agreement are for the convenience
of the parties only and shall not affect the construction or interpretation of this Agreement.

 

(c)          This
Agreement supersedes all prior agreements between the parties, including but not limited to the engagement agreement, dated April
23, 2014, by and between the Company and the Placement Agent, solely with respect to the Offering, provided that, without implication
that the contrary would otherwise be true, this Agreement shall not affect, modify, supersede, replace or terminate any agreement
between the Company and any Investor or any instrument delivered by the Company to any Investor. The parties hereto expressly acknowledge
and agree that nothing contained in any prior agreement between the Company and any Investor was intended to preclude or otherwise
prohibit any Investor from entering into this Agreement or consummating the transactions contemplated by this Agreement or from
purchasing or otherwise acquiring any Securities. The language used in this Agreement will be deemed to be the language chosen
by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. No specific
representation or warranty shall limit the generality or applicability of a more general representation or warranty. As a material
inducement for each Investor to purchase Securities, the Company expressly acknowledges and agrees that (i) no due diligence or
other investigation or inquiry conducted by any Investor, any of its advisors or any of its representatives shall affect such Investor’s
right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Company’s representations and
warranties contained in this Agreement or any other Transaction Document and (ii) unless a provision of this Agreement is expressly
preceded by the phrase “except as disclosed in the SEC Documents,” nothing contained in any of the SEC Documents shall
affect such Investor’s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Company’s
representations and warranties contained in this Agreement or any other Transaction Document. The remedies provided in this Agreement
and the other Transaction Documents shall be cumulative and in addition to all other remedies available under this Agreement and
the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief).

 

(d)          The
Company acknowledges that in connection with the Offering of the Securities: (i) the Placement Agent has acted at arms-length,
is not an agent of, and owes no fiduciary duties to the Company or any other Person, (ii) the Placement Agent owes the Company
only those duties and obligations set forth in this Agreement and (iii) the Placement Agent may have interests that differ from
those of the Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Placement
Agent arising from an alleged breach of fiduciary duty in connection with the offering of the Securities.

 

[The remainder of this page has been
intentionally left blank.]

 

    	22

    	 

    

 

 

 

Upon your execution
of this Agreement, it shall become a binding agreement enforceable against both parties in accordance with its terms.

 

Very truly yours,

 

Freeseas INC.

  

	By: 	 	 
	 	Name:  	 
	 	Title: 	 
	 	 	 
	 	Agreed and accepted as of the date first above written. 

 

DAWSON JAMES SECURITIES, INC.

 

	By:	 	 
	 	Name: Robert D. Keyser, Jr.	 
	 	Title:  Chief Executive Officer	 

 

    	23

    	 

    

 

 

Annex A

 

Crede CG III, Ltd.

 

    	24

    	 

    

 

 

Schedules

 

Schedule 2(a)

 

Adventure Two S.A.

Adventure Three S.A.

Adventure Four S.A.

Adventure Five S.A.

Adventure Six S.A.

Adventure Seven S.A.

Adventure Eight S.A.

Adventure Nine S.A.

Adventure Ten S.A.

Adventure Eleven S.A.

Adventure Twelve S.A.

Adventure Fourteen S.A.

Adventure Fifteen S.A.

 

Schedule 3(o)

 

None.

 

    	25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]